Fund moves
4.9%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PAVM · NASDAQ · Surgical & Medical Instruments & Apparatus
Pavmed (PAVM) · oqro.io/stocks/PAVM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.14−0.065 (−5.42%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Pavmed was filed in the last 90 days. The latest on record was on Dec 7, 2022.
Since 2016, Pavmed insiders reported 89 open-market purchases and 8 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2022.
No open-market sale by an insider of Pavmed (PAVM) was filed with the SEC in the last 90 days.
No trade in Pavmed (PAVM) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−89.4% (−$9.56) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $10.69 on Nov 20, 2025 to $1.14 on Nov 20, 2026 (−89.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in New York, Ny.
Last 12 months
−89.4%
Market value
$9.08M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 13K shares sold short (0.2% of shares outstanding), +0.8% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$71K
Year ended Dec 31, 2025
Net income, fiscal 2025
$401K
As reported in the annual filing
Shares outstanding
8M
As of Aug 13, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Pavmed reported 89 open-market purchases and 8 sales since 2016; purchases in 6 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $161K3×3 trades | — |
| 2021 | $32K1×1 trade | — |
| 2020 | — | $756K6×6 trades |
| 2019 | $38K2×2 trades | — |
| 2018 | $35K1×1 trade | $535K2×2 trades |
| 2017 | $47K46×46 trades | — |
| 2016 | $136K36×36 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 9,000 words.
PAVmed is a diversified commercial-stage life sciences company operating in the medical device, diagnostics, and digital health sectors. It operates through multiple independently financed subsidiaries under a shared services model. The Company’s strategy is to advance and commercialize innovative healthcare technologies through its subsidiaries while maintaining flexibility to structure financing at either the PAVmed level or within its subsidiaries.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Mar 27, 2026, compared with the one filed Mar 24, 2025. Read the filing
In the ordinary course of the Company’s business, particularly as it begins commercialization of its products, the Company may be subject to legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Revenue
$41K
+720.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$4.48M
This quarter $2.41M, a year earlier −$899K
Net debt
—
Debt —, cash $3.63M, at Sep 30, 2026
Net income, last 12 months
−$18.4M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 13, 2026.
Revenue and earnings history, 11 fiscal yearsEarnings dates and the stock's moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Off-exchange trading: 58.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.9% on ATS, 54.0% with other brokers), close to its 26-week average of 60.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (23.6%), UBS ATS (20.6%), LEVEL ATS (9.5%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Last results
Nov 13, 2026
Within the 30 days after it, until Dec 13, 2026
Next results, expected
Not announced
Purchases after results
23%
18 of 77 insider purchases since 2016 came within 30 days after a results announcement
From Pavmed's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Pavmed's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
2 certified in FY2026 Q3, vs 0 a year earlier. 2 positions in total, median offered wage $120K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.